

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Isaac BENTWICH

Serial No: 10/707,980

ATTN: GROUP DIRECTOR

Group Art Unit:

Filed : January 29, 2004

For : BIOINFORMATICALLY DETECTABLE

GROUP OF NOVEL REGULATORY GENES

AND USES THEREOF

PETITION TO MAKE SPECIAL UNDER M.P.E.P. §708.02

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The undersigned hereby petitions under M.P.E.P. §708.02 to make the above-captioned application special based upon a special status for applications relating to biotechnology filed by applicants who are small entities.

The present application is owned by Rosetta Genomics Ltd. which qualifies as a small entity as defined by 37 C.F.R. §1.27. A copy of an Assignment assigning the rights in the above-noted application to Rosetta Genomics Ltd. is attached herewith.

If the Office determines that all the claims presented are not directed to a single inventor, the applicant will make an election without traverse as a prerequisite to the grant of special accelerated examination status.

The undersigned is providing herewith a Statement relating to the importance of the above-noted application to Rosetta Genomics Ltd.

The fee required by 37 C.F.R. \$1.17(i) of \$130.00 should be charged to our Deposit Account No. 08-2455. Please charge any additional fees or credit any overpayment to our Deposit Account 08-2455.

Respectfully submitted,

Mitchell B. Wasson Reg. No. 27,408

February 4, 2004 (703)415-0100

Attorney Docket No: 04-0030.PMS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Isaac BENTWICH

ATTN: GROUP DIRECTOR

Serial No.: 10/707,980 Group Art Unit:

Filed : January 29, 2004

For : **BIOINFORMATICALLY DETECTABLE**

GROUP OF NOVEL REGULATORY GENES

AND USES THEREOF

DISCUSSION OF TECHNOLOGY CLAIMED IN PATENT APPLICATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Rosetta Genomics Ltd. (the Assignee of the above-noted U.S. patent application) is a small biotechnology company, engaged in the discovery of novel oligonucleotides associated with various disease-states, said oligonucleotides may be useful for development of next generation genomic-based therapeutics and diagnostics. The above-captioned patent application contains over 1400 bioinformatically detected oligonucleotides, which hold the potential to serve as the basis for development of therapeutics and diagnostics for several major diseases, including, but not limited to Alzheimer's disease, Multiple Sclerosis and various types of Neoplasm.

The present patent application is Rosetta Genomics' most significant and valuable asset. Timely examination, and issuance, if appropriate, of a patent for the invention disclosed in the present application are critical for successful development of therapeutics and diagnostics based thereupon.

As a small private company, Rosetta Genomics' resources are very limited. The development of therapeutics and diagnostics requires raising significant further capital from investors,

which would be virtually impossible to obtain without the prompt issuance of the present patent application.

Respectfully submitted,

Mitchell B. Wasson

Reg. No. 27,408

February 4, 2004 (703)415-0100

Attorney Docket No: 04-0030.DCT/cat